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Nature has balanced most metabolic pathways such
that no one enzyme in the pathway controls the flux
through that pathway. However, unnatural or nonna-
tive, constructed metabolic pathways may have lim-
ited product flux due to unfavorable in vivo proper-
ties of one or more enzymes in the pathway. One
such example is the mevalonate-based isoprenoid
biosynthetic pathway that we previously recon-
structed inEscherichia coli.We have used aprobable
mechanism of adaptive evolution to engineer the
in vivo properties of two enzymes (3-hydroxy-3-
methylglutaryl-CoA reductase [tHMGR] and many
terpene synthases) in this pathway and thereby elim-
inate or minimize the bottleneck created by these in-
efficient or nonfunctional enzymes. Here, we demon-
strate howwe significantly improved the productivity
(by 1000 fold) of this reconstructed biosynthetic
pathway using this strategy. We anticipate that this
strategy will find broad applicability in the functional
construction (or reconstruction) of biological path-
ways in heterologous hosts.
INTRODUCTION
It is well known that many enzymes are able to catalyze highly
specific chemical reactions with surprising accuracy and effi-
ciency (Kraut et al., 2003). In metabolic pathways, these en-
zymes, each catalyzing different reactions in a series, often
cooperate to minimize the unnecessary accumulation of meta-
bolic intermediates while maximizing the production of the final
product or optimizing the control of its production. Although nat-
ural metabolic pathways tend to be well balanced (with no one
enzyme controlling flux), constructed (heterologous) metabolic
pathways may not be so balanced, particularly when the en-
zymes for that metabolic pathway come from organisms that
are very different from the host. If the function of any single en-
zyme were suboptimal, the enzyme would cause a significant
bottleneck in the pathway, lower the yield of the final product,Chemistry & Biologyor limit the growth of the host organism. The flux through any par-
ticular step is determined by the expressability, solubility, stabil-
ity, substrate specificity, reaction selectivity, and activity (collec-
tively referred to as in vivo properties) of the enzyme catalyzing
that reaction as well as the concentration of substrates, cofac-
tors, inhibitors, and products. Although one might be able to
use traditional metabolic engineering techniques (e.g., expres-
sion modulation, promoter engineering, and codon optimization)
to overexpress a rate-limiting enzyme in a metabolic pathway to
improve flux through that pathway, a better strategy would be to
improve the in vivo properties of that rate-limiting enzyme so that
it need not be overexpressed and the amino acids and energy
needed to overexpress the enzyme would not be expended
and could be used for other cellular processes. In cases where
the in vivo properties cannot be improved by traditional
methods, improving in vivo properties may be the only method
to improve pathway flux. Therefore, the in vivo enzyme proper-
ties are important determinants of the efficiency of metabolic
pathways and should be a major concern in designing and con-
structing synthetic pathways.
We previously constructed a synthetic mevalonate pathway in
E. coli (Figure S1, see the Supplemental Data available with this
article online) and coupled it with a terpene synthase for produc-
tion of amorpha-4,11-diene (a precursor to the antimalarial drug
artemisinin) (Martin et al., 2003). Since other terpenoids have
also found use as drugs, flavors, fragrances, and nutraceuticals
and potential use as advanced biofuels, this microbial system
has become an attractive alternative to extraction from the nat-
ural host for production of these chemically complex terpenoids.
However, two reaction steps—catalyzed by anN-terminally trun-
cated 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase
(tHMGR) (Donald et al., 1997) and many terpene synthases we
have examined (Martin et al., 2001; Reiling et al., 2004)—have
been identified as the primary bottlenecks in this synthetic path-
way as the result of their unfavorable in vivo properties. That
these two enzymes limited product formation was evident by
the data showing that expressing amorpha-4,11-diene synthase,
an enzymewith excellent in vivo properties, significantly reduced
the accumulated farnesyl diphosphate (FPP) and allowed pro-
duction of large titers of amorpha-4,11-diene (over 200 mg/l)
and that vastly overexpressing the gene encoding tHMGR
improved terpene production (Pitera et al., 2007). Although15, 607–618, June 2008 ª2008 Elsevier Ltd All rights reserved 607
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terpene synthases have much lower activity in vivo (Martin
et al., 2001; Reiling et al., 2004). Not only do terpene synthases
and tHMGRhave poor in vivo properties, the substrates for these
enzymes (HMG-CoA and FPP, respectively) appeared to be
toxic and inhibit the growth of E. coli when they accumulated
inside the cell (Martin et al., 2003; Pitera et al., 2007). However,
the products of these enzymes (mevalonate and sesquiterpenes,
respectively) do not interfere with host growth and are readily
secreted into the medium.
The genes for the terpene biosynthetic pathwaywere encoded
in three separate constructs. The MevT operon contains the
genes encoding the enzymes in the top part of the pathway (ace-
tyl-CoA to mevalonate: atoB encoding acetoacetyl-CoA thio-
lase, ERG13 encoding HMG-CoA synthase [HMGS], and the 30
portion of HMG1 [without the 50 portion of the gene encoding
the membrane-binding N terminus of the enzyme] encoding
tHMGR [Figure S1A]). The MBIS operon contains the genes en-
coding the bottom part of the pathway (mevalonate to FPP:
ERG12 encoding mevalonate kinase [MK], ERG8 encoding
phosphomevalonate kinase [PMK],MVD1 encoding mevalonate
diphosphate decarboxylase [MVD], idi encoding isopentenyl di-
phosphate isomerase, and ispA encoding prenyl diphosphate
synthase [Figure S1B]). The third construct consists of the ter-
pene synthase, which catalyzes the conversion of the prenyl
diphosphates (geranyl-, farnesyl-, and geranylgeranyl diphos-
phates) to various terpenes with different regio- and stereo-
chemistry (Figure S1C).
An example of a terpene synthase with poor in vivo properties
is g-humulene synthase (HUM). HUM is a sesquiterpene syn-
thase from the gymnosperm Abies grandis that is known to pro-
duce at least 52 different sesquiterpene olefins from FPP through
a wide variety of carbocation reaction mechanisms (Steele et al.,
1998). On the basis of the theory of divergent molecular evolu-
tion, we previously demonstrated the redesign of many specific
mutant variants that produce a single or a few terpenes (Martin
et al., 2003; Yoshikuni et al., 2006a; Yoshikuni and Keasling,
2007). Because of its versatility and plasticity in catalysis, HUM
might find use in industrial terpenoid production and is an excel-
lent model to study the biochemistry of terpene synthases. How-
ever, the overexpression of HUMwith this system resulted in the
formation of less than 0.02 mg/l of terpenes even after expres-
sion optimization at 37C. Detailed analyses have revealed that
a large fraction of HUM misfolds and accumulates in the insolu-
ble fraction. As a result, only a small fraction of this enzyme is
functional in vivo. Although various genetic tools have been tried
to improve expression of this enzyme, none of these strategies
has worked well. Because of the potential importance of this
enzyme and the difficulties in increasing its activity in vivo, we
have chosen this enzyme and its specific mutant variants as
models for redesign.
As has been discussed, since in vivo properties are strongly
dependent on innate characteristics of enzymes, neither tradi-
tional nor more recently developed metabolic engineering strat-
egies (Pitera et al., 2007) are likely to improve poorly functioning
enzymes. Instead, protein engineering strategies that actually
improve the function of these enzymes might be very useful or
even become the sole solution to these problems. Protein engi-
neering has been widely adopted as an effective design strategy608 Chemistry & Biology 15, 607–618, June 2008 ª2008 Elsevier Ltdto improve many different enzyme properties. However, the ap-
plication of conventional protein engineering strategies, such as
directed evolution (Roodveldt et al., 2005) and rational and com-
putational design (Daujotyte et al., 2003; Nasreen et al., 2006),
are extremely difficult or nearly impossible for such enzymes
as HUM and other terpene synthases because of the lack of
both a high-throughput screen and enzyme structures with
atomic level accuracy. Although several screening methodolo-
gies using fused reporter proteins have been previously de-
scribed, the reporter activity is not necessarily correlated with
the activity of the target proteins and, hence, a large number of
mutants still need to be screened (Yoshikuni et al., 2006b).
In addition, since it is thought that each terpene synthase has
evolved after a series of speciation events, the primary se-
quences of terpene synthases of diverse function are more re-
lated within an organism or closely related organisms than are
terpene synthases of similar function but in very different organ-
isms. Primary sequences for terpene synthases are limited and
biased to the enzymes derived from model species. Thus, it is
also extremely difficult to extract useful information from a con-
ventional analysis of their evolutionary relationship (Amin et al.,
2004; Lehmann et al., 2002; Steipe et al., 1994). Furthermore, be-
cause the function of these enzymes is highly plastic, any single
mutation introduced into a terpene synthase could alter its prod-
uct selectivity. Therefore, a methodology that does not affect
product selectivity would be ideal. For these reasons, we have
considered how evolution might essentially optimize and main-
tain the favorable in vivo properties of enzymes and thereby ef-
ficiencies of metabolic pathways. Here, we present a simple
and fast redesign strategy for enzymes based on plausible
mechanisms of molecular evolution and demonstrate its use
on two enzymes (tHMGR, HUM, and its specific mutant variants)
whose in vivo activities have been difficult to improve using
traditional metabolic engineering techniques.
RESULTS AND DISCUSSION
Immutability of Amino Acids
In nature, pathways are thought to be constructed and gradually
optimized through adaptive evolution of each enzyme in the
pathway to render the host organisms adaptable to changing
environments (Schmidt et al., 2003). In molecular evolution, the
fixation probability of mutations is primarily determined by their
fitness effects if a population size is small, which can be delete-
rious (opposed by purifying selection and likely discarded from
a population), neutral or nearly neutral (genetic drift), or advanta-
geous (generated through positive selection and fixed in a popu-
lation) (Pal et al., 2006). It has been proposed that many enzymes
are horizontally transferred from one species to another and are
subsequently adapted to the new intracellular environment (Pal
et al., 2005). Therefore, when mutations to a particular amino
acid at a given position are kept to a minimum in this process
(less mutable), then these amino acids are probably more essen-
tial for maintaining the in vivo properties of that enzyme. If such
amino acids could be identified, then it would be possible to im-
prove their function in the host organisms by properly realigning
these amino acids on the basis of evolutionary relationships of
that enzyme.All rights reserved
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mutability of amino acids, the results have not been consistent
and appear to change with the types of proteins being analyzed
(Endo et al., 2002; Graur, 1985). To reconcile these findings, we
analyzed over 30,000 homologous sequences to over 200 differ-
ent E. coli enzymes involved in central metabolism across multi-
ple species (see Experimental Procedures for details). Because
of the essential roles of central metabolic enzymes in host viabil-
ity, the in vivo properties of these enzymes are expected to be
optimal. The probabilities of mutations to each amino acid X be-
tween two sequences (PXMut) and that for all amino acids (PMut)
were determined (see Experimental Procedures for more infor-
mation); interestingly, PXMut and PMut were linearly correlated in
many cases (Figures 1A–1D). Thus, we are able to determine
which amino acid contributes most to the diversification of
Figure 1. Evolutionary Study of the Relative
Stability for Each Amino Acid
An immutability of each amino acid (likelihood to
gain and loss by substitutions, insertions, and de-
letions) was calculated by comparing over 200
E. coli proteins involved in central metabolism
and each of their homologs (30,000 total), and it
was converted to free energy difference (DGXMut ;
kT* denotes arbitrary unit). A probability of muta-
tion to each amino acid XðPXMutÞ was plotted
against that for all amino acids (PMut ) using the glu-
tamate synthase large subunit protein family as an
example; plots for alanine (PAMut=PMuty1) (A), glu-
tamine (PQMut=PMut > 1) (B), glycine (P
G
Mut=PMut <1)
(C), and proline (PPMut=PMut < 1) (D) are shown.
The average of the relative stability for each amino
acid to mutations obtained from analyses of 209
different protein families (or superfamilies) is
shown (E: mean ± 2 SE). The results clearly indi-
cate that Gly and Pro were significantly more im-
mutable over the course of evolution.
enzymes. The average PXMut=PMut for
each amino acid X was determined and
then used to calculate the change in
free energy due to the amino acid change
(DGXMut) (Figure 1E). The analysis clearly
indicates that Gly and Pro are signifi-
cantly less mutable, compared with other
amino acids in E. coli central metabolic
enzymes. The results imply that Gly and
Pro are more essential and have been ac-
quired or maintained or both during the
adaptation of these enzymes toward
function in E. coli.
Redistribution of Gly and Pro
Residues at Predicted Positions
in Proteins
As mentioned above, through prior work
in our laboratory, we determined that
tHMGR and HUM limited flux through
the terpene biosynthetic pathway (Pitera
et al., 2007; Yoshikuni et al., 2006a). Al-
though both enzymes were expressed at a high level, neither en-
zyme had sufficient in vivo activity. Thus, we focused our work on
these twoenzymes.Weselectively redistributedGly andProboth
in tHMGR and HUM on the basis of their evolutionary relation-
ships to other HMGRs and terpene synthases, respectively. First,
multiple sequence alignments (MSAs) for both tHMGR and HUM
were constructed. The MSA for tHMGR was constructed using
other HMGR sequences derived from Archaea, because HMGR
from Archaea is produced in soluble form. The MSA for HUM
was constructed using mono- and diterpene synthases derived
from gymnosperms, because only few sesquiterpene synthases
derived from gymnosperms have been discovered. Next, the
probabilities of conservation for Gly (PGi ) and Pro (P
P
i ) at each
ith residue of tHMGR and HUM were calculated (represented
in blue and red bars, respectively, in Figures 2A and 2C forChemistry & Biology 15, 607–618, June 2008 ª2008 Elsevier Ltd All rights reserved 609
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Enzyme Redesign for Optimal Biosynthetic PathwaystHMGR and in Figures 3A and 3C for HUM). Finally, substitutions
involving Gly and Pro were introduced to both tHMGR and HUM
according to the predicted profiles.
For the case that the product of particular enzyme does not
impact cell physiology and the reaction step catalyzed by this
enzyme is the primary bottleneck in a biosynthetic pathway, it
can be assumed that improvements to the in vivo properties of
the enzyme will be directly reflected in its product formation
and that mutational effects can be easily evaluated. Therefore,
the fitness effects of these mutations on tHMGR and HUM
were monitored by the level of in vivo mevalonate and sesquiter-
pene production, respectively (represented by the blue and red
bars, respectively, in Figures 2B and 2D for tHMGR and Figures
3B and 3D for HUM).
In both cases, the predictions were greater than 80% accurate
(Gly- and Pro-related mutations are represented by the blue and
red dots, respectively in Figures 3E and 3F, and Figures 4E and
4F); the exceptions were the residues that did not align well in
MSAs (represented by the yellow bars in Figures 3A–3D and Fig-
ures 4A–4D). In the case of HUM, the effects of mutations to
residues predominantly conserved in either mono- or diterpene
synthases (represented by the green and purple bars in Figures
3A–3D, respectively) were difficult to evaluate, because changes
to these residues substantially impacted enzyme activity. As
such, the quality of the MSA would significantly affect the
accuracy of the predictions. Although the MSA for HUM was
constructed primarily from mono- and diterpene synthases, rel-
atively high correlation between product formation and probabil-
ity of conservation was observed (represented by the blue and
red dots in Figures 3E and 3F for HUM). The correlation for
tHMGR was not as good as that for HUM (represented by the
blue and red dots in Figures 2E and 3F). Because the pathway
containing the native tHMGR was already capable of producing
mevalonate at almost 10% of its theoretical maximum, mevalo-
nate production could be improved only a few fold. Thus, im-
provement to the in vivo properties of tHMGR did not have as
significant impact on mevalonate production as improvements
on HUM had on sesquiterpene production. It is also interesting
to note that the method was good at predicting the effects of cu-
mulative neighbor mutations. For example, introduction of each
of the tHMGR mutants G353A and G349A resulted in increased
mevalonate production even though the mutations were pre-
dicted to reduce mevalonate production. However, when these
mutations were introduced into the G352A mutant, these muta-
tions decreased mevalonate production (10%–40% reduction in
mevalonate productivity, comparedwith that fromG352A alone).
Thus, the methodology accurately predicted the effect of cumu-
lative neighbor mutations.Chemistry & BiologFinally, to determine whether another amino acid might be
a better change at these positions, saturation mutagenesis
was performed on G148, G227, G327, and G361 in HUM. In all
cases, substitution of the native amino acid with Ala improved
sesquiterpene production, and no further mutations were con-
sidered.
Accumulation of Single Mutations Improved the In Vivo
Enzyme Properties and Production of Various Terpenes
Mutations that improved the invivopropertiesof tHMGRandHUM
were subsequently recombined, and the effects of mutations on
their in vivo properties were cumulative; we have constructed
the tHMGR-G9 mutant containing the changes P200A/G206A/
T239P/G319A/G352A/G417A/P428G/K474G/G495A and HUM-
G6 mutant containing the changes K126P/R142G/G148A/
G227A/G327A/G361A. When integrated into the host alone,
tHMGR-G9 increased mevalonate production three fold, and
HUM-G6 improved sesquiterpene production 80 fold (Figure 4B
and Figure 5B, respectively). The improvements in product titer
were due to increases in flux through the pathway as well as im-
provements in growth, as E. coli harboring tHMGR-G9 did not
suffer the growth inhibition of accumulated HMG-CoA that the
strain harboring wild-type tHMGR did (Figure 4A and Figure 5A).
When the tHMGR-G9 and HUM-G6 mutants were integrated
into the same host, host growth improved by three to four fold,
and sesquiterpene production improved by nearly 1000 fold (Fig-
ures 5A and 5B).
The same mutations that were introduced into HUM-G6 were
also introduced into six previously designed, mutant variants of
HUM that produced a few or a single product rather than the
many products generated by HUM (Yoshikuni et al., 2006a);
the effects of mutations on their in vivo properties were similar
to that of HUM. The terpene productivities of the host harboring
these improved enzymes were also dramatically improved (8–34
mg/l from 0.02 mg/l; Figure 5C). Given that the conservation
analysis is supported for over 200 different enzyme families (or
superfamilies), we predict that similar mutations could improve
the in vivo properties of many other enzymes.
The Effects of Gly- and Pro-Related Mutations
on Enzyme Activity
To investigate howGly and Pro redistributions contribute to such
a large improvement in sesquiterpene production, product se-
lectivity, steady state kinetics, and in vivo sesquiterpene produc-
tion from S-tagged versions of HUM, HUM-G3 (K126P/R142G/
G227A), and HUM-G6 were measured. (The S-tag was removed
for the steady state kinetics study). Although terpene synthases
are known to be very plastic (Yoshikuni et al., 2006a; YoshikuniFigure 2. MSA-Predicted Gly and Pro Redistributions in tHMGR and Their Effect on Mevalonate Production
Distributions of Gly, represented in blue bars in (A), and Pro, represented in red bars in (C), to have effect on the in vivo properties of tHMGRwere predicted on the
basis of an MSA constructed using the primary sequences of HMGR derived from Archaea as a guide (sharing 30%–40% sequence identity). Residues that did
not align in theMSA are represented by yellow bars in these figures. According to these profiles, Gly/Ala, Xaa/Gly, Pro/Ala, and Xaa/Pro substitutions were
introduced into tHMGR, and functional consequences for these substitutions were monitored by in vivo mevalonate production. The effects caused by Gly/Ala
and Xaa/Gly mutations are represented by the blue bars in (B), the effects caused by Pro/Ala and Xaa/Pro mutations are represented by the red bars in (D),
and the effects caused by mutations to the residues that did not align in the MSA are represented by the yellow bars in (B) and (D) (mean ± SD of triplicate mea-
surements). The correlation between the fitness effects caused bymutations andPi
x, are plotted in (E) and (F). Gly/Xaa and Pro/Xaamutations are represented
by the blue and red dots, respectively, in (E), and the Xaa/Gly and Xaa/Pro mutations are represented by the blue and red dots, respectively, in (F). These
results show that over 80% of the aligned mutations were accurately predicted from these profiles using Pi = 0.4 as a threshold. Pi = 0.4 was chosen for threshold
because the MSA was constructed using homologous sequences with 30%–40% identity.y 15, 607–618, June 2008 ª2008 Elsevier Ltd All rights reserved 611
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ble to that of wild-type HUM (Table 1). In addition, its activity
(kcat/Km) was similar to that of wild-type HUM (Table 1). In con-
trast, in vivo sesquiterpene production from S-tagged HUM-G6
increased nearly two fold over that of the non-S-tagged HUM-
G6. The improvement in sesquiterpene production from HUM
to HUM-G6 increased with temperature (3.3-fold at 20C, 10-
fold at 30C, and 220-fold at 37C; Figure 6A). Of all the temper-
atures tested, wild-type HUM showed the highest terpene pro-
duction at 30C, whereas HUM-G6 showed the highest terpene
production at 37C. Given that more enzyme was found in the
soluble fraction at 37C than at 30C (Figure 6B), it appears
that wild-type HUM does not fold properly at higher tempera-
tures (many enzymes found even in the soluble fraction at
37Cwere not functional) and that Gly and Pro redistributions in-
creased the ability of HUM-G6 to functionally fold in the E. coli
intracellular environment at higher temperature. In fact, quantifi-
cation of in vivo enzyme levels in both the soluble fraction and
crude lysate revealed that the mutations significantly improved
the concentration of soluble enzymes (Figure 6C).
SIGNIFICANCE
Wesuccessfully redesigned the in vivo properties of tHMGR,
HUM, and its six specific mutant variants to improve in vivo
sesquiterpene production without affecting the respective
catalyzed reactions. Because of their unfavorable in vivo
properties, these enzymes have been previously found to
be significant bottlenecks in the terpene biosynthetic path-
way. From our initial analysis of over 30,000 homologs to
over 200 E. coli enzymes involved in central metabolism,
Gly and Pro were initially suggested to be essential for their
in vivo properties. These amino acids were then selectively
redistributed in tHMGR and HUM on the basis of their evolu-
tionary relationships. The results show that this protein en-
gineering strategy is simple and fast, but yet powerful and
effective to redesign in vivo enzyme properties without alter-
ing product distributions, a task that would have been
extremely difficult or nearly impossible using conventional
protein engineering strategies. Since proper distributions
of these amino acids can be predicted largely from their evo-
lutionary relationships and their redistribution dramatically
impacted the flux through the heterologous, biosynthetic
pathway, it is likely that proper distributions of these amino
acids are essential for many enzymes expressed in E. coli
and could have been achieved primarily as a result of adap-
tive evolution. Together with our previous studies (Yoshikuni
et al., 2006a; Yoshikuni and Keasling, 2007), these resultsChemistry & Biologyprovide evidence that protein engineering strategies based
on the theories of molecular evolution are very useful for
design and construction of synthetic systems.
EXPERIMENTAL PROCEDURES
Reagents and Equipments
All enzymes and chemicals were purchased from New England Biolabs and
Sigma-Aldrich, respectively, unless otherwise stated. An HP6890 gas chro-
matograph equipped with a 5973 mass selective detector (Hewlett Packard)
or flame ionization detector, a CyclosilB capillary column (30 m 3 250 mm
i.d. 3 0.25 mm thickness; Agilent Technologies) or DB5-MS capillary column
(30 m3 250 mm i.d.3 0.25 mm thickness; Agilent Technologies), and a Combi
PAL auto sample-injector (LEAP Technologies) were used for analysis. An
Figure 4. Integration of Redesigned tHMGR into E. coli and the
Resulting Mevalonate Production
The growth (A) andmevalonate production (B) for strains harboring pBADMevT
containing tHMGR-WT (yeast wild-type HMG1p of its membrane binding
domain truncated), tHMGR-G5 (G206A/G319A/G352A/G417A/G495A), and
tHMGR-G9 (P200A/G206A/T239P/G319A/G352A/G417A/P428G/K474G/G495A)
were measured. Both the growth and mevalonate production improved ap-
proximately 2.5–3-fold, and the increase in growth is proportional to the
increase in mevalonate production. We previously demonstrated that accu-
mulation of HMG-CoA inhibits cell growth. Thus, improving the in vivo proper-
ties of tHMGR reduced HMG-CoA accumulation and thus the toxicity of the
pathway.Figure 3. MSA-Predicted Gly and Pro Redistributions in HUM and Their Effect on Sesquiterpene Production
Distributions of Gly, represented by blue bars in (A), and Pro, represented by red bars in (C), to have effect on the in vivo properties of HUMwere predicted on the
basis of an MSA constructed using the primary sequences of mono-, sesqui-, and diterpene synthases derived from gymnosperms as a guide. Residues that did
not align, aligned only inmonoterpene synthases, and aligned only in diterpene synthases inMSA are represented by yellow, green, and purple bars, respectively.
According to this profile, Gly/Ala, Xaa/Gly, Pro/Ala, and Xaa/Pro substitutions were introduced into HUM, and the fitness effects of these substitutions
were monitored by in vivo sesquiterpene production. The effects caused by Gly/Ala and Xaa/Gly mutations are represented by the blue bars in (B), the effects
caused by Pro/Ala and Xaa/Pro mutations are represented by red bars in (D), and mutations to residues that did not align in MSA are represented by yellow
bars in (B) and (D) (mean ± SD of triplicate measurements). The correlation between the fitness effects by mutations and Pi
x is shown in (E) and (F). Gly/Xaa and
Pro/Xaa mutations are represented by blue and red dots, respectively, in (E), and Xaa/Gly and Xaa/Pro mutations are represented by blue and red dots,
respectively, in (F). These results indicate that over 80%–90% of the aligned mutations were accurately predicted from these profiles with Pi = 0.4 as a threshold;
Pi = 0.4 was chosen for threshold because the MSA was constructed using homologous sequences with 30%–40% identity.15, 607–618, June 2008 ª2008 Elsevier Ltd All rights reserved 613
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the Synthetic Pathway and the Resulting In Vivo Sesquiterpene
Production
E. coli DH1 harboring pBADMevT (tHMGR-WT or tHMGR-G9 [P200A/G206A/
T239P/G319A/G352A/G417A/P428G/K474G/ G495A]), pBBRMBIS, and
pTrcHUM15 (containing HUM-WT, HUM-G3 [K126P/R142G/G227A], or HUM-
G6 [K126P/R142G/G148A/G227A/G327A/G361A]) was used for in vivo ses-
quiterpene production. The growth curve (A) and sesquiterpene production
at 24 hr after inoculation (B) are shown. HUM-WT, HUM-G3, and HUM-G6
cointegrated with tHMGR are shown in light blue, medium blue, and dark blue,
respectively, and those with tHMGR-G9 are shown in yellow, light green,
and dark green, respectively. The strain containing tHMGR-G9 grew 3-fold
higher and produced 3-foldmoremevalonate (Figure 4), resulting in a synergis-
tic improvement in overall sesquiterpene production. The mutations in HUM-
G6 were also applied to specific variants of HUM previously constructed in
our laboratory (SIB, sibirene synthase; sHUM, specific g-humulene synthase;
LFN, longifolene synthase; ALP, a-longipinene synthase; BBA, b-bisabolene614 Chemistry & Biology 15, 607–618, June 2008 ª2008 Elsevier LtdLS6500 multipurpose scintillation counter (Beckman Coulter) was used for
enzyme kinetics.
Analysis of Amino Acid Composition Changes in Proteins
across Multiple Species
To examine the relative importance of each of 20 different amino acids (X: Ala,
Cys, Asp..), we calculated relative immutability (likelihood to gain and loss by
substitutions, deletions, and insertions) for each amino acid from over 200 dif-
ferent protein families (or superfamilies), and it was fitted to free energy differ-
ence (DGXMut ). These protein families are all involved in central metabolism,
including glycolysis, citric acid cycle, pentose phosphate pathway, oxidative
phosphorylation, fatty acid metabolism, amino acid metabolism, and nucleic
acid metabolism. In each protein family (or superfamily) (F), each homologous
protein sequence (H) was searched using the basic local alignment search tool
for proteins (BLASTP: http://www.ncbi.nih.gov). In pair-wise alignment
between a particular E. coli protein sequence and its homologous protein
sequence derived from a particular species, the probability of mutations
(PXMut;H;F ) for each amino acid (X) was calculated on the basis of the composi-
tion of all aligned pairs of amino acids described by the following formula:
PXMut;H;F =
NXMut;H;F
NX
where NXMut;H;F and N
X denote the number of amino acid pairs only one and at
least one of which is X in each pair-wise alignment, respectively. The pair-wise
alignments used herein covered at least 80% of and shared over 50% identity
to thecorrespondingE.coliproteinsequences. For this calculation,weassumed
that if proteins had evolved without any constraint, the PXMut;H;F should be iden-
tical to that for all amino acids (PMut;H;F ) described as the following formula:
PMut;H;F =
NMut;H;F
N
where NMut;H;F denotes the number of mutated amino acid pairs, and N
denotes the number of all amino acid pairs in each pair-wise alignment. We,
then, plotted PXMut;H;F against PMut;H;F . On average, 164 (2 3 SE = 22) plots
(pair-wise sequence alignments) were made for each of over 200 protein fam-
ilies. PXMut;F=PMut;F is defined as the slope for the linear regression of the data in
the plot. The free energy difference of each amino acid X for the mutations in
each protein family (or superfamily) F (DGXMut;F ) was then calculated according
to Boltzmann statistics as follows:
PXMut;F
PMut;F
= exp
 
DGXMut;F
kT
!
where kT* denotes an arbitrary constant. In this analysis, we calculated
DGXMut;F only when the R
2 of the PXMut;F=PMut;F plot was greater than 0.9 or
0.7 if the plots were distributed symmetrically about the trend line to minimize
the bias introduced by duplicate or nearly duplicate plots.
Design Methodology to Improve In Vivo Properties of Enzymes
Using MSA as a Guide
To predict where to distribute Gly, Pro, and Xaa (where Xaa denotes any amino
acid residues other than Gly and Pro), we first created an MSA for both HUM
and tHMGR using MUSCLE (http://phylogenomics.berkeley.edu/cgi-bin/
muscle/input_muscle.py). The primary sequence of HUM from the gymno-
sperm Abies grandis was aligned with other mono-, sesqui-, and diterpene
synthases derived from gymnosperms. Although many sesquiterpene syn-
thases have been isolated from angiosperms, mono- and diterpene synthases
from gymnosperms are more closely correlated to HUM at the primary se-
quence level. The primary sequence of tHMGR derived from yeast, which
was solubilized for expression in E. coli by removal of the N terminus, was
aligned with other orthologous sequences derived from archaeal species, as
the archaeal HMGR is produced in a soluble form as opposed to the mem-
brane-bound form found in most eukaryotes. The conservation probability
synthase; and AYG, a-ylangene synthase) were cointegrated with tHMGR-
G9 (C). The resulting specific terpene production at 48 hr after inoculation im-
proved dramatically for each variant and is compared to total sesquiterpene
production for G6. All data represent mean ± SD of triplicate measurements.All rights reserved
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Namea Mutations
Kinetic Parametersb Product Distributionsc,d
kcat (10
3 s1) Km (mM) kcat/Km (10
3 M1s1) 1 2 3 4 5 6
WT None 12.00 ± 0.34 2.01 ± 0.17 5.96 8.3 7.2 14.9 26.1 34.0 9.5
G3 K126P, 142G, G227A 7.62 ± 0.21 4.66 ± 0.39 1.64 7.2 6.3 16.5 27.9 31.7 10.4
G6 K126P, 142G, G148A,
G227A, G327A G361A
1.71 ± 0.17 0.69 ± 0.13 2.47 7.1 6.8 15.2 27.4 32.8 10.7
SIB K126P, 142G, G148A,
G227A, G327A G361A,
F312Q, M339A, M447F
ND ND ND 0.2 2.8 2.2 80.1 13.8 0.9
HUM K126P, 142G, G148A,
G227A, G327A G361A,
M339N, S484C, M565I
ND ND ND 5.6 11.7 5.9 0.7 75.6 0.6
LFN K126P, 142G, G148A,
G227A, G327A G361A,
A317Ne,A336S, S484C,
I562V
ND ND ND 12.8 3.4 62.1 1.6 11.9 8.1
ALP K126P, 142G, G148A,
G227A, G327A, G361A,
A336C, T445C, S484C,
I562L, M565L
ND ND ND 60.2 4.6 13.7 0.4 14.6 6.5
BBA K126P, 142G, G148A,
G227A, G327A, G361A,
A336V, M447H, I562T
ND ND ND 1.6 0.2 3.9 0.5 4.7 89.1
AYG K126P, 142G, G148A,
G227A, G327A, G361A,
S484A, Y566F
ND ND ND 14.6 27.5 0.5 0.6 47.1 9.6
Bold type indicates products that enzymes were designed to produce.
aWT, wild type ghumulene synthase; G3, third generation of mutant ghumulene synthase; G6, sixth generation of mutant ghumulene synthase;
SIB, sibirene synthase; HUM, new ghumulene synthase; LFN, longifolene synthase; ALP, alongipinene synthase; BBA, bbisabolene synthase;
AYG, aylangene synthase.
bND: parameters were not determined for a particular mutant.
c 1, alongipinene; 2, aylangene; 3, longifolene; 4, sibirene; 5, ghumulene; 6, bbisabolene.
d All product distributions were represented for 1–6 as 100%; these are corresponding tomore than 85%–95%and to 75%of total products inmutants
and wild type (including G3 and G6), respectively.
e A317N occurred during recombination, and improved in vivo terpene production without a change in product distribution.for Gly (PGi ) and Pro (P
P
i ) at column i in a givenMSAwas calculated on the basis
of the composition of Gly and Pro at column i as follows:
PXi =
NXi
Ni
where NXi and Ni denote the number of amino acid X (Gly or Pro) and the total
number of aligned amino acids at position i in each column of theMSA, respec-
tively. The fitness effects contributed by these mutations were predicted to be
dependent on the value ofPi; we usedP
X
i = 0:4 as a threshold because each se-
quence used to construct MSA shared approximately 35%–40% identity with
HUM or tHMGR.We compared the value of PXi and the fitness effects resulting
from singlemutations; whenPXi R0:4, themutation to amino acid X is predicted
to show neutral, nearly neutral, or positive fitness effects and away from amino
acid X to show neutral, nearly neutral, or negative fitness effects. When
PXi %0:4, the mutation to amino acid X is predicted to show neutral, nearly neu-
tral, or negative fitness effects and away from amino acid X to show neutral,
nearly neutral, or positive fitness effects. For example, if X is Gly, PGlyi is larger
than 0.4, and the ith residue is Gly, the residue remains Gly; if the ith residue is
any residue other than Gly, the residue is changed to Gly. If PGlyi is smaller than
0.4 and if the ith residue is Gly, the residue is changed to Ala; if the ith residue is
any residue other than Gly, the residue remains unchanged.
Strains and Plasmids
E. strains DH10B and DH1 were used for both mevalonate and sesquiterpene
production, and BL21(DE3) was used for protein overexpression and purifica-Chemistry & Biologytion. Plasmids pBADMevT (Martin et al., 2003) and their mutant variants were
used for mevalonate production. Plasmid pBBRMBIS (Martin et al., 2003) was
used for FPP production. Plasmids pTrcHUM (Yoshikuni et al., 2006a),
pTrcHUM15, and their mutant variants were used for sesquiterpene produc-
tion (Figure S1). Plasmid pTrcSHUM15 and its mutant variants were used for
quantification of protein concentrations in vivo. Plasmids pETHUM (Yoshikuni
et al., 2006a) and its mutant variants were used for protein overexpression and
purification. All genes in pBADMevT and pTrcHUM have been previously re-
synthesized, and their codon usage has been optimized.
Since reduced expression of HUM slightly improved sesquiterpene produc-
tion, an extra seven base pairs were introduced between the ribosome-bind-
ing-site (RBS) and the start codon at theNcoI site of pTrcHUM. The RBS region
was amplified by polymerase chain reaction (PCR): 98C for 30 sec, 55C
for 30 sec, and 72C for 30 sec, repeated 30 times. The reaction mixture con-
tained 13Phusionbuffer, 2mMdNTP, 0.5mMforward (50-GCGCGTTGGTGCG
GATATC-30) and reverse (50-CATGCCATGGAGCTTATTCTGTTTCCTGTGT
GAAATTG-30) primers, 2.5 U Phusion DNA polymerase (Finezyme), and 50 ng
pTrcHUM as a template in a total volume of 100 ml. The amplified fragments
were then digested with EcoRV/NcoI and inserted into the corresponding site
of pTrcHUM to form pTrcHUM15.
pTrcSHUM15 was constructed on the basis of pTrcHUM15 backbone. The
S-tag was fused to the N-terminal of HUM. The RBS region in pTrcHUM15was
amplified by PCR: 98C for 30 sec, 55C for 30 sec, and 72C for 30 sec, re-
peated for 30 times. The reaction mixture contained 13 Phusion buffer,
2 mM dNTP, 0.5 mM forward (50-GCGCGTTGGTGCGGATATC-30) and reverse15, 607–618, June 2008 ª2008 Elsevier Ltd All rights reserved 615
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Enzyme Redesign for Optimal Biosynthetic PathwaysFigure 6. Investigation of the Temperature Effects for Gly and Pro
Mutations
S-tagged versions HUM-WT (yellow), HUM-G3 (light green), and HUM-G6
(dark green) were cointegrated with tHMGR-G9 into the synthetic pathway
to examine the effect of temperature on accumulated Gly and Pro mutations.
Sesquiterpene production by these strains (A), total HUM protein concentra-
tion in culture (B), and soluble HUM protein concentration in culture (C) at
24 hr after inoculation are shown. The OD600 reached approximately 2.5 at
20C, 8.0 at 30C, and 6.5 (G6)-8.0 (WT) at 37C. Interestingly, sesquiterpene
productivity from HUM-G6 improved almost 1.7-fold with an N-terminal S-tag.
The higher the temperature, the more HUM was produced. At 37C, the
amount of HUM-G6 in the soluble fraction was significantly higher than that
of HUM-WT. All data represent mean ± SD of triplicate measurements.616 Chemistry & Biology 15, 607–618, June 2008 ª2008 Elsevier Lt(50-GCAGCAGCGGTTTCTTTCATGGAGCTTATTCTGTTTC-30) primers, 2.5 U
Phusion DNA polymerase (Finezyme), and 50 ng pTrcHUM15 as a template
in total volume of 100 ml. The S-tag was amplified by PCR: 98C for 30 sec,
55C for 30 sec, and 72C for 30 sec, repeated for 30 times. The reaction mix-
ture contained 13 Phusion buffer, 2 mM dNTP, 0.5 mM forward (50-GAAACA
GAATAAGCTCCATGAAAGAAACCGCTGCTGC-30) and reverse (50-CATGC
CATGGAACCGCGTGGC-30) primers, 2.5 U Phusion DNA polymerase
(Finezyme), and 50 ng pET29 (Novagen) as a template in a total volume of
100 ml. These two amplified fragments were spliced by overlap PCR: 98C
for 30 sec, 55C for 30 sec, and 72C for 30 sec, repeated for 30 times.
The reaction mixture contained 13 Phusion buffer, 2 mM dNTP, 0.5 mM for-
ward (50-GCGCGTTGGTGCGGATATC-30) and reverse (50-CATGCCATG
GAACCGCGTGGC-30) primers, 2.5 U Phusion DNA polymerase (Finezyme),
and the above-mentioned fragments as a template in a total volume of 100 ml.
The spliced fragment was then digested with EcoRV/NcoI and inserted into the
corresponding site of pTrcHUM to form pTrcSHUM15.
GC-MS Analysis for In Vivo Mevalonate Production
To screen the single mutation library, a single colony harboring pBADMevT
(wild-type tHMGR or its mutant variants) was inoculated into Luria Bertani
(LB) medium containing Cm50 and grown overnight at 37C. An aliquot (50 ml)
of this seed culture was inoculated into fresh LB medium (5 ml) containing
Cm50 and 13.3mM (+)-L-arabinose andwas grown for 24 hr at 37C. An aliquot
of culture (560 ml) was mixed with 140 ml of 0.5 M HCl to dehydrate the meval-
onate to form mevalonolactone, and 700 ml of ethyl acetate was then added to
the sample. The mixture was vortexed for 5 min, and the ethyl acetate was
analyzed by GC-MS using a GC oven temperature program of 90C for
1min, then ramping 30C/min to 250C for CyclosilB capillary column analysis.
Mevalonolactone was identified from its mass spectrum and retention time by
comparison to an authentic standard.
As for the final mevalonate production assay, a single colony harboring
pBADMevT (wild-type tHMGR or its mutant variants) was inoculated into LB
medium containing Cm50 and grown overnight at 37C. An aliquot (500 ml)
of this seed culture was inoculated into fresh modified m9 medium (50 ml,
see above formulation) containing Cm50. Two hours after the inoculation,
(+)-L-arabinose was added to the final concentration of 13.3 mM. Mevalonate
production was analyzed as mentioned above.
GC-FID and GC-MS Analysis for In Vivo Sesquiterpene Production
To screen the single mutation library, a single colony harboring pTrcHUM
(wild-type HUM or its mutant variants) and pBBRMBIS was inoculated into
LB medium containing 50 mg/ml carbenicillin (Cb50) and 50 mg/ml kanamycin
(Km50) and grown overnight at 37C. An aliquot (50 ml) of this seed culture
was inoculated into fresh LBmedium (5ml) containing 10mMD/L-mevalonate,
Cb50, and Km50, overlaid with 500 ml dodecane, and was grown for 24 hr at
37C. An aliquot of dodecane (50 ml) was diluted into 200 ml of ethyl acetate,
and the mixture was analyzed by GC-MS or GC-FID using a GC oven temper-
ature program of 80C for 1 min, then ramping 30C/min to 110C, 5C/min to
160C, and 130C/min to 250C for CyclosilB capillary column analysis and of
80C for 3 min, then ramping 5C/min to 160C, and 120C/min to 300C for
DB-5MS capillary column analysis. Camphor was used as an internal stan-
dard. Sesquiterpenes were identified from their mass spectra and GC reten-
tion times by comparison to available authentic standards and spectra in
libraries previously reported in the literature.
As for the final sesquiterpene production assay, a bacterial system contain-
ing three plasmids was used (Martin et al., 2003). A single colony harboring
pTrcHUM15 or pTrcSHUM15 (wild-type HUM or its mutant variants),
pBBRMBIS, and pBADMevT (wild-type tHMGR [Donald et al., 1997] or its mu-
tant variants) was inoculated into LB medium containing Cb50, Km50, and
chloramphenicol (Cm50) and was grown for overnight at 37C. An aliquot of
this seed culture was inoculated into 50 ml of fresh, modified, M9 medium
(M9 salt, 75 mM MOPS, 3% glycerol, 5 g/l yeast extract, 2 mM MgSO4,
1 mg/l thiamine, 10 mM FeSO4, 0.01 mM CaCl2, and micronutrient [pH 7]) to
the final OD600 of 0.05 containing Cb
50, Km50, and Cm50, overlaid with 10 ml
of dodecane. Two hours after the inoculation, isopropyl-b-D-thiogalactopyra-
nosid (IPTG) and (+)-L-arabinose were added to the final concentrations of
1 mM and 13.3 mM, respectively. Sesquiterpene production was analyzed
as mentioned above.d All rights reserved
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Site-directed mutagenesis for tHMGR was performed using overlap PCR
(Table S1 for the primer sequences used herein). DNA fragments encoding
the N and C termini of the mutation were amplified by PCR: 98C for 30 sec,
55C for 30 sec, and 72C for 30 sec, repeated for 30 times. The reaction mix-
ture contained 13 Phusion buffer, 2 mM dNTP, 0.5 mM forward and reverse
primers, 2.5 U Phusion DNA polymerase (Finezyme), and 50 ng pBADMevT
as a template for tHMGR in a total volume of 100 ml. The amplified DNA frag-
ment was gel purified using a gel purification kit (QIAGEN) or treated with DpnI
and purified using a PCR purification kit (QIAGEN). These two amplified DNA
fragments were spliced via overlap PCR: 98C for 30 sec, 55C for 30 sec,
and 72C for 30 sec, repeated for 30 times. The reaction mixture contained
13 Phusion buffer, 2 mM dNTP, 0.5 mM forward and reverse primers, 2.5 U
Phusion DNA polymerase (Finezyme), and 50 ng of the above-mentioned
DNA fragments as a template in a total volume of 100 ml. The fully amplified
HMGR fragment was digested with SpeI/HindIII and inserted into the corre-
sponding site of pBADMevT.
Site-Directed Mutagenesis of HUM by Overlap PCR
Site-directed mutagenesis of HUM was performed using overlap PCR (Table
S2 for the primer sequences used herein). DNA fragments encoding the N
and C terminus of the mutation were amplified by PCR: 98C for 30 sec,
55C for 30 sec, and 72C for 30 sec, repeated 30 times. The reaction mixture
contained 13 Phusion buffer, 2 mM dNTP, 0.5 mM forward and reverse
primers, 2.5 U Phusion DNA polymerase (Finezyme), and 50 ng pTrcHUM in
100 ml as a template for g-humulene synthase. Amplified DNA was gel purified
using a gel purification kit (QIAGEN) or treated with DpnI and purified using
a PCR purification kit (QIAGEN). These two amplified DNA fragments were
spliced via overlap PCR: 98C for 30 sec, 55C for 30 sec, and 72C for
30 sec, repeated for 30 times. The reaction mixture contained 13 Phusion
buffer, 2 mM dNTP, 0.5 mM forward and reverse primers, 2.5 U Phusion DNA
polymerase (Finezyme), and 50 ng of the above-mentioned DNA fragments as
a template in a total volume of 100 ml. The fully amplified HUM fragment was
digested with NcoI/XbaI and cloned into the corresponding site in pTrcHUM.
Quantification of In Vivo HUM Concentrations
A single colony harboring pTrcSHUM15 (wild-type or its mutant variant),
pBBRMBIS, and pBADMevT was inoculated into LB medium containing
Cb50, Km50, and Cm50 and was grown overnight at 37C. An aliquot of this
seed culture was inoculated into fresh modified M9 medium (50 ml, see above
formulaton) containing Cb50, Km50, and Cm50 to the final OD600 of 0.05 and
was grown at 37C. Two hours after the inoculation, IPTG and (+)-L-arabinose
was added to the final concentrations of 1 mM and 13.3 mM, respectively. The
cultures were then grown at 20C, 30C, and 37C. An aliquot of culture (1 ml)
was taken and centrifuged at 14,000 3 g. The resulting pellet was resus-
pended into Bugbuster containing recommended amount of Lysonase (Nova-
gen) to the final OD600 of 20, and it was incubated for half an hour at room tem-
perature. This lysis solution was centrifuged for 10min at 14,0003 g. Total cell
lysate (24 ml) (both soluble and insoluble fractions) and the soluble fraction only
(24 ml) were mixed with 75 ml of 8 M guanidinium chloride and 1 ml of 4 M dithio-
threitol. These solutions were incubated for another hour at room temperature.
The concentration of HUM was determined by FRET Works S-tag assay kit
following the recommended protocols (Novagen). In vivo sesquiterpene pro-
duction from each culture was measured as described above.
Protein Expression and Purification of HUM
Wild-type HUM and its variants were cloned into pET29 and transformed into
BL21 (DE3). Each transformant was inoculated into LB medium (5 ml) contain-
ing Km50 and was grown overnight at 30C. An aliquot (2 ml) of this seed cul-
ture was inoculated into fresh terrific broth (TB) medium containing Km50
(500 ml), and the culture was grown at 30C. When the culture reached OD600
of 0.6–0.8, 0.1 mM of IPTG was added, and the culture was grown at 20C for
another 16 hr. Cells were harvested by centrifugation at 6,000 3 g for 15 min.
The pellet was suspended in 50 ml of BugBuster (Novagen) containing 20 U
DNaseI and bacterial protease inhibitor cocktail II (Novagen) and was incu-
bated for an hour at 4C. The solution was centrifuged at 20,000 3 g for
30 min and then was filtered through a 0.45-mm filter. S-tag Thrombin puri-
fication kit (Novagen) was used for the purification following the protocolChemistry & Biologyrecommended by Novagen. All purifications were done at half scale. The
eluted protein solution was dialyzed twice (PIERCE, MW 3,000 Da) against
1 l of buffer containing 10 mM Tes (pH 7.0), 10 mM MgCl2, 1 mM DTT, and
5% glycerol overnight. The protein concentration was measured using the
Bradford method. We obtained approximately 3 ml of 25–500 mg/ml of protein
solution with about 95% purity (confirmed by SDS-PAGE gel, data not shown).
Enzyme Kinetics
The kinetics studies of HUMand its variants were performed following a slightly
modified protocol from that previously reported by Little and Croteau (2002).
Kinetics for each enzyme was measured in a 40 ml reaction containing 0.15–
0.4 mM enzyme, in buffer described in the previous section and overlaid with
dodecane. The concentration of FPP varied from 0.229 to 58.6 mMwith a fixed
ratio of [3H]FPP. Seven to nine different concentrations of FPP were used for
each enzyme (n = 3). The reaction mixture was incubated for 20 min at
31C. To stop the reaction, 40 ml of a solution containing 4 M NaOH and 1 M
EDTA was added and mixed. To extract sesquiterpene products, the reaction
mixture was vortexed for 2 min, and 400 ml of dodecane was taken from the
solution andmixed with 15ml of scintillation fluid. Radioactivity wasmeasured
by scintillation counting. kcat, Km and kcat/Km were calculated using Enzyme
Kinetics!Pro (ChemSW).
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